[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@EuroBiotechNews European Biotech
European Biotech posts on X about $1bn, $350m, $650m, $157m the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXX -XX%
- X Month XXXXX +41%
- X Months XXXXX +149%
- X Year XXXXX +813%
Mentions: X #
- X Week X -XX%
- X Month XX -XX%
- X Months XX +74%
- X Year XX +1,243%
Followers: XXXXX #
- X Week XXXXX -XXXX%
- X Month XXXXX -XXXX%
- X Months XXXXX -XXXX%
- X Year XXXXX -XXXX%
CreatorRank: undefined #
Social Influence #
Social category influence finance XX% stocks XX%
Social topic influence $1bn 10%, $350m 10%, $650m 10%, $157m 10%, novartis 10%, $rna 10%, $12bn 10%, aoc XX%
Top assets mentioned Novartis AG (NVS) Avidity Biosciences, Inc. Common Stock (RNA)
Top Social Posts #
Top posts by engagements in the last XX hours
"Ipsen acquires ImCheck in US$1bn deal Pharma giant Ipsen will pay US$1bn to acquire French immuno-oncology firm ImCheck Therapeutics SAS. The deal includes US$350m upfront and up to US$650m in milestone payments. ImCheck focuses on butyrophilins"
X Link @EuroBiotechNews 2025-10-22T09:53Z 4005 followers, XX engagements
"Synbio alliance strengthens EU corticosteroid supply chain The French AI-synbio specialist Abolis Biotechnologies SAS has entered a strategic 140m alliance with API manufacturer EuroAPI SA under the IPCEI Med4Cure funding programme. Within the co"
X Link @EuroBiotechNews 2025-10-24T07:50Z 4006 followers, XX engagements
"Hemab Therapeutics bags in Series C financing Hemab TherapeuticsA/S has completed an oversubscribed US$157m Series C financing round. The round was led by Sofinnova Partners with significant participation from a large long-only global asset ma"
X Link @EuroBiotechNews 2025-10-27T14:53Z 4006 followers, XX engagements
"Novartis acquires Avidity Biosciences for US$12bn In a major bet on RNA medicine Swiss Novartis AG announced to buy Avidity Biosciences Inc for US$12bn. Avidity's Oligonucleotide Conjugate (AOC) platform allows Transferin receptor-targeted RNA de"
X Link @EuroBiotechNews 2025-10-28T10:16Z 4006 followers, XX engagements